Citi Upgrades GlaxoSmithKline (GSK) to Buy
Tweet
Share
E-mail
Get Alerts GSK Hot Sheet
Price: $51.96 -1.74%
Rating Summary:
6 Buy, 16 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
6 Buy, 16 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Citi upgraded GlaxoSmithKline (NYSE: GSK) from Neutral to Buy.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $43.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- BNP Paribas Exane Upgrades Pony AI Inc (PONY) to Outperform
- Futu Holdings Limited (FUTU) PT Raised to $157 at Citi
Create E-mail Alert Related Categories
UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
